[1] [1] Sun Z, Ji J, Zuo L, et al. Causal relationship between nonalcoholic fatty liver disease and different sleep traits: a bidirectional Mendelian randomized study[J]. Front Endocrinol (Lausanne), 2023, 14: 1159258.

[2] [2] Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2022, 7(9): 851-861.

[3] [3] Hsu PF, Wang YW, Lin CC, et al. The association of the steatosis severity in fatty liver disease with coronary plaque pattern in general population[J]. Liver Int, 2021, 41(1): 81-90.

[4] [4] Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications[J]. Gut, 2020, 69(9): 1691-1705.

[5] [5] Barchetta I, Cimini FA, Cavallo MG. Vitamin D and metabolic dysfunction-associated fatty liver disease (MAFLD): an update[J]. Nutrients, 2020, 12(11): 3302.

[6] [6] Holick MF. The vitamin D deficiency pandemic: Approaches for diagnosis, treatment and prevention[J]. Rev Endocr Metab Disord, 2017, 18(2): 153-165.

[8] [8] Bennour I, Haroun N, Sicard F, et al. Vitamin D and obesity/adiposity-a brief overview of recent studies[J]. Nutrients, 2022, 14(10): 2049.

[9] [9] Pop TL, Srbe C, Bena G, et al. The role of vitamin D and vitamin D binding protein in chronic liver diseases[J]. Int J Mol Sci, 2022, 23(18): 10705.

[10] [10] Liu T, Xu L, Chen FH, et al. Association of serum vitamin D level and nonalcoholic fatty liver disease: a meta-analysis[J]. Eur J Gastroenterol Hepatol, 2020, 32(2): 140-147.

[11] [11] Heo NJ, Park HE, Yoon JW, et al. The Association between vitamin D and nonalcoholic fatty liver disease assessed by controlled attenuation parameter[J]. J Clin Med, 2021, 10(12): 2611.

[12] [12] Zhang JJ, Yu HC, Li Y, et al. Association between serum 25-hydroxy vitamin D concentrations and mortality among individuals with metabolic dysfunction-associated fatty liver disease: a prospective cohort study[J]. Am J Clin Nutr, 2022, 116(5): 1409-1417.

[13] [13] Zhang X, Shang X, Jin S, et al. Vitamin D ameliorates high-fat-diet-induced hepatic injury via inhibiting pyroptosis and alters gut microbiota in rats[J]. Arch Biochem Biophys, 2021, 705: 108894.

[14] [14] Zhang XL, Chen L, Yang J, et al. Vitamin D alleviates non-alcoholic fatty liver disease via restoring gut microbiota and metabolism[J]. Front Microbiol, 2023, 14: 1117644.

[15] [15] Elhafiz M, Zhao G, Ismail M, et al. Imbalanced insulin substrate-1 and insulin substrate-2 signaling trigger hepatic steatosis in vitamin D deficient rats: 8-methoxypsoralen, a vitamin D receptor ligand with a promising anti-steatotic action[J]. Biochim Biophys Acta Mol Cell Biol Lipids, 2020, 1865(6): 158657.

[16] [16] Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy[J]. J Hepatol, 2020, 72(3): 558-577.

[17] [17] Fakhoury HMA, Kvietys PR, AlKattan W, et al. Vitamin D and intestinal homeostasis: Barrier, microbiota, and immune modulation[J]. J Steroid Biochem Mol Biol, 2020, 200: 105663.

[18] [18] Lee PC, Hsieh YC, Huo TI, et al. Active vitamin D3 treatment attenuated bacterial translocation via improving intestinal barriers in cirrhotic rats[J]. Mol Nutr Food Res, 2021, 65(3): e2000937.

[19] [19] Albhaisi S, Noureddin M. Current and potential therapies targeting inflammation in NASH[J]. Front Endocrinol (Lausanne), 2021, 12: 767314.

[20] [20] Calton EK, Keane KN, Newsholme P, et al. The impact of vitamin D levels on inflammatory status: a systematic review of immune cell studies[J]. PLoS One, 2015, 10(11): e0141770.

[21] [21] Dong B, Zhou Y, Wang W, et al. Vitamin D receptor activation in liver macrophages ameliorates hepatic inflammation, steatosis, and insulin resistance in mice[J]. Hepatology, 2020, 71(5): 1559-1574.

[22] [22] Liu Y, Wang M, Xu W, et al. Active vitamin D supplementation alleviates initiation and progression of nonalcoholic fatty liver disease by repressing the p53 pathway[J]. Life Sci, 2020, 241: 117086.

[23] [23] Ma M, Long Q, Chen F, et al. Active vitamin D impedes the progression of non-alcoholic fatty liver disease by inhibiting cell senescence in a rat model[J]. Clin Res Hepatol Gastroenterol, 2020, 44(4): 513-523.

[24] [24] Zhu CG, Liu YX, Wang H, et al. Active form of vitamin D ameliorates non-alcoholic fatty liver disease by alleviating oxidative stress in a high-fat diet rat model[J]. Endocr J, 2017, 64(7): 663-673.

[25] [25] Mirhosseini N, Vatanparast H, Mazidi M, et al. Vitamin D supplementation, glycemic control, and insulin resistance in prediabetics: a meta-analysis[J]. J Endocr Soc, 2018, 2(7): 687-709.

[26] [26] Szymczak-Pajor I, Drzewoski J, liwiska A. The molecular mechanisms by which vitamin D prevents insulin resistance and associated disorders[J]. Int J Mol Sci, 2020, 21(18): 6644.

[27] [27] Mohater S, Qahtan S, Alrefaie Z, et al. Vitamin D improves hepatic alterations inACE1 andACE2 expression in experimentally induced metabolic syndrome[J]. Saudi Pharm J, 2023, 31(9): 101709.

[28] [28] Du T, Xiang L, Zhang J, et al. Vitamin D improves hepatic steatosis in NAFLDviaregulation of fatty acid uptake and -oxidation[J]. Front Endocrinol (Lausanne), 2023, 14: 1138078.

[29] [29] Ciardullo S, Muraca E, Cannistraci R, et al. Low 25 (OH) vitamin D levels are associated with increased prevalence of nonalcoholic fatty liver disease and significant liver fibrosis[J]. Diabetes Metab Res Rev, 2023, 39(5): e3628.

[30] [30] Sun S, Xu M, Zhuang P, et al. Effect and mechanism of vitamin D activation disorder on liver fibrosis in biliary atresia[J]. Sci Rep, 2021, 11(1): 19883.

[31] [31] El Amrousy D, Abdelhai D, Shawky D. Vitamin D and nonalcoholic fatty liver disease in children: a randomized controlled clinical trial[J]. Eur J Pediatr, 2022, 181(2): 579-586.

[32] [32] Chen X, Zhao Y, Zhang R, et al. The effect of vitamin D supplementation on some metabolic parameters in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of 8 RCTs[J]. Medicine (Baltimore), 2023, 102(42): e35717.